{
    "clinical_study": {
        "@rank": "116058", 
        "arm_group": [
            {
                "arm_group_label": "Lorazepam", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of 2-mg\n      lorazepam intravenous administration in healthy Japanese adult subjects."
        }, 
        "brief_title": "Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese male and/or female subjects of non-childbearing potential.\n\n          -  Body Mass Index of 17.5 to 30.5 kg/m2; and a total body weight >50 kg.\n\n        Exclusion Criteria:\n\n          -  History of sensitivity to lorazepam or other benzodiazepines.\n\n          -  Evidence or history of acute narrow-angle glaucoma or sleep apnea syndrome.\n\n          -  Significant psychiatric disorder, recurrent episodes of severe depression, or\n             subjects with serious suicidal risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994668", 
            "org_study_id": "B3541001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lorazepam", 
                "description": "A single intravenous administration of 2 mg lorazepam over 1 minute", 
                "intervention_name": "Lorazepam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "A single intravenous administration of 0.9% saline over 1 minute", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lorazepam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "lorazepam", 
            "intravenous", 
            "pharmacolinetics", 
            "healthy", 
            "Japanese"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3541001&StudyName=Phase%201%20Study%20to%20Characterize%20the%20Safety%20and%20Pharmacokinetics%20of%20Single%20Intravenous%20Dose%20of%20Lorazepam%20in%20Healthy%20Japanese%20Adult%20Subjects"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Hachioji-shi", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized Single-blind (Subject-blind), Placebo Controlled Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.", 
            "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs).", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to  Day 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994668"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day1 to Day 4"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}